Enovis (NYSE:ENOV) Price Target Raised to $38.00

Enovis (NYSE:ENOV) had its price target boosted by analysts at Needham & Company LLC from $34.00 to $38.00 in a research note issued on Thursday, Benzinga reports. The firm presently has a “buy” rating on the stock. Needham & Company LLC‘s price objective points to a potential upside of 33.36% from the company’s current price.

Other equities analysts have also recently issued research reports about the stock. UBS Group reiterated a “buy” rating and issued a $44.00 price objective on shares of Enovis in a research note on Monday, October 5th. Canaccord Genuity Group dropped their price objective on shares of Enovis from $50.00 to $45.00 and set a “buy” rating on the stock in a report on Monday, August 17th. Citizens Jmp cut their target price on shares of Enovis from $55.00 to $47.00 and set a “market outperform” rating for the company in a research report on Wednesday, September 2nd. Wall Street Zen raised shares of Enovis from a “hold” rating to a “buy” rating in a report on Saturday, October 31st. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Enovis in a report on Wednesday, September 2nd. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Enovis currently has a consensus rating of “Moderate Buy” and an average target price of $38.50.

Enovis Stock Performance

Enovis stock traded up $4.08 during mid-day trading on Thursday, reaching $28.50. 5,319,363 shares of the stock traded hands, compared to its average volume of 1,269,304. Enovis has a 12-month low of $16.70 and a 12-month high of $32.41. The business’s 50-day moving average is $19.79 and its 200-day moving average is $23.05. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.98 and a quick ratio of 1.00. The stock has a market capitalization of $1.64 billion, a PE ratio of -1.48 and a beta of 1.31.

Enovis (NYSE:ENOV) last announced its earnings results on Thursday, November 5th. The company reported $0.88 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.77 by $0.11. The business had revenue of $558.73 million for the quarter, compared to analysts’ expectations of $557.12 million. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%. The business’s revenue for the quarter was up 1.8% on a year-over-year basis. During the same period last year, the firm posted $0.75 earnings per share. As a group, sell-side analysts predict that Enovis will post 3.15 EPS for the current fiscal year.

Insider Buying and Selling at Enovis

In other news, insider Oliver Engert acquired 2,660 shares of the firm’s stock in a transaction dated Friday, September 4th. The shares were purchased at an average cost of $18.80 per share, for a total transaction of $50,008.00. Following the transaction, the insider directly owned 63,898 shares of the company’s stock, valued at approximately $1,201,282.40. This trade represents a 4.34% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Damien Mcdonald bought 13,035 shares of the stock in a transaction that occurred on Friday, September 4th. The shares were purchased at an average price of $19.15 per share, for a total transaction of $249,620.25. Following the purchase, the chief executive officer owned 247,077 shares in the company, valued at $4,731,524.55. This represents a 5.57% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought a total of 23,293 shares of company stock worth $449,599 over the last 90 days. Insiders own 2.90% of the company’s stock.

Institutional Investors Weigh In On Enovis

A number of institutional investors and hedge funds have recently bought and sold shares of ENOV. Illinois Municipal Retirement Fund lifted its position in shares of Enovis by 22.4% in the third quarter. Illinois Municipal Retirement Fund now owns 38,366 shares of the company’s stock valued at $701,000 after acquiring an additional 7,028 shares in the last quarter. Private Management Group Inc. grew its position in shares of Enovis by 31.3% during the third quarter. Private Management Group Inc. now owns 1,792,429 shares of the company’s stock worth $32,748,000 after purchasing an additional 427,347 shares in the last quarter. Fulcrum Asset Management LLP grew its position in shares of Enovis by 2,739.4% during the third quarter. Fulcrum Asset Management LLP now owns 20,330 shares of the company’s stock worth $375,000 after purchasing an additional 19,614 shares in the last quarter. Villanova Investment Management Co raised its stake in Enovis by 10.2% during the 3rd quarter. Villanova Investment Management Co now owns 148,424 shares of the company’s stock valued at $2,712,000 after purchasing an additional 13,740 shares during the period. Finally, Bfsg LLC raised its stake in Enovis by 24.6% during the 3rd quarter. Bfsg LLC now owns 13,282 shares of the company’s stock valued at $243,000 after purchasing an additional 2,622 shares during the period. 98.45% of the stock is owned by institutional investors.

Enovis News Roundup

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: Enovis reported Q3 earnings of $0.88 per share, topping analyst estimates of about $0.76–$0.77 and improving from $0.75 a year earlier. Revenue of $558.7 million was slightly above consensus, though year-over-year growth was modest at 1.8%. Enovis Q3 2026 results
• Positive Sentiment: The company announced a $200 million share buyback, which could support per-share results and signal management confidence in the business. Enovis announces $200 million equity buyback
• Positive Sentiment: BTIG Research raised its price target to $42 from $36 and maintained a Buy rating, adding to the bullish outlook after the earnings release. BTIG Research ratings
• Neutral Sentiment: Revenue was close to expectations, so the earnings beat was driven more clearly by per-share earnings than by stronger-than-expected sales growth.
• Negative Sentiment: Fundamentals provided with the report show a sharply negative net margin, a profitability concern despite the quarterly EPS beat.

About Enovis

Enovis Corporation (NYSE: ENOV) is a medical technology company that develops, manufactures and distributes products designed to improve patient recovery, mobility and quality of life. Its portfolio serves orthopedic, sports medicine, physical therapy and rehabilitation markets, as well as other areas of musculoskeletal care.

The company’s products include orthopedic implants and surgical technologies, braces and supports, cold and compression therapy systems, electrotherapy and rehabilitation equipment, and other solutions used by hospitals, surgeons, physical therapists, athletic trainers and patients.